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Abstract
Background: Anti-neutrophil cytoplasmic antibodies (ANCA) is autoantibodies characteristic of
vasculitis diseases. A connection between ANCA and Wegener's granulomatosis was well
established. The interaction of both ANCA phenotypes (PR3-ANCA and MPO-ANCA) with
leukocytes provoked cell activation, which might be involved in the pathogenesis of ANCA-related
Wegener's granulomatosis.
Methods: In this study, we examined whether PR3-ANCA sera and purified immunoglobulins
from patients with Wegener's granulomatosis prime human monocytic cells for enhanced
responses to microbial components in terms of production of proinflammatory cytokines.
Results: Flow cytometry demonstrated that stimulation with antibodies to proteinase 3 enhanced
the expression of TLR2, 3, 4, 7, and 9, NOD1, and NOD2 in human mononuclear cells. The sera
and purified immunoglobulins significantly primed human mononuclear cells to secrete interleukin-
8 in response to microbial components via TLRs and NODs. Priming effects were also observed
for the production of interleukin-6, monocyte chemoattractant protein-1, and tumor necrosis
factor-α. On the other hand, PR3-ANCA-negative sera from patients with polyarteritis nodosa
which possibly related to MPO-ANCA and aortitis syndrome as well as control sera from a healthy
volunteer did not have any priming effects on PBMCs.
Conclusion: In conclusion, PR3-ANCA prime human mononuclear cells to produce cytokines
upon stimulation with various microbial components by up-regulating the TLR and NOD signaling
pathway, and these mechanisms may partially participate in the inflammatory process in Wegener's
granulomatosis.
Background
Anti-neutrophil cytoplasmic antibodies (ANCA) form a
heterogeneous group of Abs that target antigens present
mostly in azurophilic granules of polymorphonuclear
leukocytes. ANCA were first discovered in the 1970s,
when cytoplasmic fluorescence was observed during
investigations of anti-nuclear antibodies (Abs) by indirect
fluorescence on human granulocytes [1]. In the 1980s, the
spectrum of diseases associated with ANCA became
clearer, and vasculitis [2,3] was identified as a common
sign of these diseases. A connection between ANCA and
Wegener's granulomatosis (WG) was established [4].
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ANCA are directed against antigens located in the cyto-
plasmic space of polymorphonuclear leukocytes and
monocytes. Two of the main targets have been identified
as enzymes, both part of the azurophilic granules of neu-
trophils; these enzymes are proteinase 3 (PR3) [5] and
myeloperoxidase (MPO) [6]. The antigenic specificity of
ANCA may be illustrated by immunofluorescent labeling,
during an investigation of ANCA on ethanol-fixed granu-
locytes. The cytoplasmic fluorescence forms a characteris-
tic picture of PR3-ANCA and is mainly associated with
reactivity to PR3, whereas perinuclear fluorescence reflects
MPO-ANCA, the target for which is represented, in most
cases, by MPO [7].
ANCA have been reported to be causally involved in the
pathogenesis of WG; the autoantibody titer correlates
with disease activity [8], and ANCA directly activate a wide
variety of inflammatory functions in neutrophils, such as
the secretion of oxygen radicals, proteases, and lipid
mediators, once PR3 is expressed on the leukocyte surface
[9-12] under inflammatory conditions. Additionally, in
isolated monocytes, anti-PR3 Abs stimulate the release of
proinflammatory cytokines [13,14]. Nowack et al. [15]
reported that the expression of CD14 and CD18 was up-
regulated on monocytes by ANCA as well as monoclonal
Abs against PR3 in vitro. Anti-PR3 Abs provoked a marked
release of cytokines in human monocytes with the early
appearance of tumor necrosis factor (TNF)-α and interle-
kin (IL)-1β and the delayed release of IL-6, IL-8, and
thromboxane A2 [16]. In addition, anti-PR3 Abs induced
the release of monocyte chemoattractant protein (MCP)-
1 from human mononuclear cells [17]. Hatter et al. [18]
reported that PR3 was detected in human renal tubular
epithelial cells treated with TNF-α, and the primed cells
responded to anti-PR3 Abs with the activation of a phos-
phoinositide-related signal transduction pathway.
Recently, Bartùòková et al. [19] reported that the interac-
tion of PR3-ANCA with TNF-α-primed mononuclear cells
stimulated the release of IL-8 via cross-linking between Fc
gamma receptors and PR3 expressed on the monocyte cell
surface. More recently, Hattar et al. [20] demonstrated a
priming effect of PR3-ANCA for the activation of isolated
monocytes and neutrophils by bacterial cell-surface com-
ponents such as lipopolysaccharide (LPS) and lipotei-
choic acid. Although the incubation of monocytes and
neutrophils with ANCA alone resulted in only a low level
of IL-8 release, preincubation with ANCA, but not with
isotype-matched control immunoglobulin (Ig)G, resulted
in a markedly enhanced release of IL-8 upon stimulation
with LPS. ANCA-related priming was also observed for the
production of TNF-α and IL-6. Flow cytometric analysis
revealed an increase in the expression of CD14 on mono-
cytes and neutrophils following the priming with ANCA.
Therefore, they concluded that ANCA specifically prime
monocytes and neutrophils in a CD14-dependent man-
ner, and the resulting enhanced responsiveness to bacte-
rial components may contribute to the development and
maintenance of inflammatory lesions during WG.
The innate immune system recognizes microorganisms
through a series of pattern recognition receptors that are
highly conserved in evolution, specific for common
motifs found in microorganisms but not in eukaryotes,
and designated as pathogen-associated molecular patterns
(PAMPs) [21-23]. Representative microbial PAMPs are the
lipid A moiety of LPS from Gram-negative bacteria,
lipopeptides from various bacteria, including myco-
plasma, peptidoglycans (PGNs) from either Gram-posi-
tive or Gram-negative bacteria except mycoplasma which
are devoid of cell walls and viral double-stranded and sin-
gle-stranded RNA. Several studies have demonstrated that
in mammals, these PAMPs are recognized specifically by
the respective Toll-like receptor (TLR) [24]. In addition,
NOD-like receptor (NLR) family members were demon-
strated to be intracellular receptors for partial structures of
PGN; NOD1 and NOD2 recognize a diaminopimelic acid
(DAP) containing peptide moiety [25,26] and a
muramylpeptide moiety [27,28], respectively.
Previously, we demonstrated that PR3 activated human
oral epithelial cells [29] and human gingival fibroblasts
[30] via protease-activated receptor (PAR)-2. Further-
more, we demonstrated that proinflammatory cytokines
induced production of PR3 in human oral epithelial cells,
and the addition of murine anti-PR3 Abs to cytokine-
primed oral epithelial cells induced the aggregation of
PR3 followed by the activation of protease-activated
receptor (PAR)-2, which resulted in remarkable secretion
of IL-8 and MCP-1 [31]. Recently, we revealed that murine
anti-human PR3 monoclonal Ab primed human mono-
cytic THP-1 cells for enhanced activation upon stimula-
tion by various TLR- and NOD-ligands [32]. In this study,
we examined whether PR3-ANCA serum and purified IgG
from WG patients were truly capable of activating human
peripheral blood mononuclear cells (PBMCs) similary to
the combination of murine anti-human PR3 Abs and
THP-1 cells to release proinflammatory cytokines. If they
are, the mechanism might be involved in the pathogenesis
of ANCA-related chronic inflammatory diseases repre-
sented by WG.
Methods
Serum and immunoglobulin (Ig) samples
ANCA sera were obtained from 4 patients with WG at
Tohoku University Hospital from Sep 1996 to Apr 2000.
Sera from polyarteritis nodosa patients and aortitis syn-
drome patients were also obtained from totally 4 patients.
The samples were immediately clarified by centrifugation,
aliquoted, and frozen at -70°C until used. PR3-ANCA and
MPO-ANCA titers were re-confirmed by EIA method byDiagnostic Pathology 2009, 4:23 http://www.diagnosticpathology.org/content/4/1/23
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BML Co. (Sendai, Japan). All of the 4 ANCA sera used in
this study were PR3-ANCA-positive and MPO-ANCA-neg-
ative specimens, and sera from polyarteritis nodosa and
aortitis syndrome were PR3-ANCA-negative and MPO-
ANCA-negative (Table 1). Normal serum from a healthy
adult donor was used as a control. Purified Ig was pre-
pared by absorption on protein G from the representative
samples of PR3-ANCA sera and one sample of normal
serum. The IgGs were negative for endotoxin in a Limulus
amoebocyte lysate assay (sensitivity, 0.1 ng/ml). Prior to
use, the IgGs were centrifuged to remove aggregates. For
comparative purposes, a murine monoclonal anti-human
PR3 Ab obtained from CLB (Amsterdam, The Nether-
lands) was used.
Reagents
The synthetic MDP (MurNAc-L-Ala-D-isoGln) and syn-
thetic  Escherichia coli-type lipid A (LA-15-PP) were
obtained from The Protein Research Foundation Peptide
Institute (Osaka, Japan). Poly I:C was purchased from
Sigma-Aldrich (St. Louis, MO, USA). Single-stranded (ss)
Poly U was acquired from Invivogen (San Diego, CA,
USA). A conventional CpG DNA, CpG DNA 1826
(TCCATGACGTTCCTGACGTT [CpG motif is under-
lined]), was purchased from SIGMA Genosys (Tokyo,
Japan). The synthetic diacyl lipopeptide FSL-1 (S-[2,3-
bis(palmitoyloxy)-(2RS)-propyl]-[R]-cysteinyl-GDP-
KHPKSF) was obtained from EMC microcollections
(Tübingen, Germany). The synthetic desmuramylpep-
tides, a PGN fragment containing DAP, FK156 (D-lactoyl-
L-Ala-γ-D-Glu-meso-DAP-Gly) [33] was supplied by Astel-
las Pharmaceutical Co. (Tokyo, Japan). Anti-TLR2 mAb
(TL2.1) (mouse IgG), anti-TLR3 mAb (mouse IgG), anti-
TLR4 mAb (HTA125) (mouse IgG), anti-TLR7 mAb
(mouse IgG), and anti-TLR9 mAb (mouse IgG) were pur-
chased from eBioscience (San Diego, CA, USA). Rabbit
anti-NOD1 Ab (L-17) and rabbit anti-NOD2 Ab were
obtained from Santa Cruz Biotechnology (Santa Cruz, CA,
USA). Isotype control mouse IgG (MOPC-2) was pur-
chased from Sigma-Aldrich. All other reagents were
obtained from Sigma-Aldrich, unless otherwise indicated.
Cells and cell culture
The human monocytic leukemia cell line THP-1, supplied
by the Health Science Research Resources Bank (Osaka,
Japan), was cultured in RPMI 1640 medium (Nissui Sei-
yaku, Osaka, Japan) with 10% heat-inactivated fetal calf
serum (FCS) at 37°C in a humidified CO2 atmosphere.
The THP-1 cells were maintained in a logarithmic phase of
growth (2 × 105 to 2 × 106) by passage every 3–4 days.
Human PBMCs were isolated from heparinized periph-
eral blood of healthy adult donors by Lympholyte-H
(Cedarlane Laboratories, Hornby, Ontario, Canada) gra-
dient centrifugation at 800 × g for 20 min at room temper-
ature. The isolated PBMCs were washed three times with
phosphate-buffered saline (PBS) and suspended in RPMI
1640 medium.
Determination of cytokines in culture supernatants
The cells were collected and washed twice in PBS. They (2
× 105 cells per ml) were preincubated with anti-PR3 Ab,
control Abs, PR-ANCA sera or control sera for 6 h. Subse-
quently, they were stimulated with or without a stimulant
in RPMI 1640 medium with 10% FCS for 24 h in 96-well
culture plates. The culture supernatants were collected and
the levels of IL-6, IL-8, MCP-1 and TNF-α were deter-
mined with an ELISA kit (OptEIA ELISA Kits, BD
Pharmingen). The concentrations of the cytokines in the
supernatants were determined using the LS-PLATEman-
ager 2004 data analysis program (Wako Pure Chemical
Industries, Osaka, Japan).
Flow cytometry
Flow cytometric analyses were performed using a FACS-
Calibure cytometry (BD Biosciences, Mountain View, CA,
USA). PBMCs were stained with anti-TLR2 Ab and anti-
TLR4 Ab or control IgG at 4°C for 30 min, followed by flu-
Table 1: Titers of PR3-ANCA and MPO-ANCA in serum from WG patients, polyarteritis nodosa patients, and aortitis syndrome 
patients used in this study.
No. (sample code) (bleeding date) PR3-ANCA (U/ml) MPO-ANCA (U/ml)
1. (Q9-40) (5/9/1996) 29.2 < 1.3
(R9-10) (9/27/1996) 19.1 < 1.3
(S9-31) (11/21/1996) 10.7 < 1.3
2. (R9-7) (9/27/1996) 3.8 < 1.3
(S9-29) (11/19/1996) 3.5 < 1.3
3. (S9-32) (11/21/1996) 18.8 < 1.3
4. (D10-41) (4/4/2000) 14.0 < 1.3
5. (M10-24) (2/3/2004) < 1.3 < 1.3
6. (M10-28) (2/3/2004) < 1.3 < 1.3
7. (G10-37) (5/15/2002) < 1.3 < 1.3
8. (H10-51) (9/2/2002) < 1.3 < 1.3Diagnostic Pathology 2009, 4:23 http://www.diagnosticpathology.org/content/4/1/23
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orescein isothiocyanate (FITC)-conjugated secondary Ab
(BioSource International, Camarillo, CA, USA) at 4°C for
an additional 30 min. For TLR3, TLR7, TLR9, NOD1 and
NOD2, intracellular staining was performed. Briefly, the
cells were washed with staining buffer, fixed and permea-
bilized with BD Cytofix/Cytoperm solution (BD Bio-
sciences) for 15 min at 4°C, and then incubated with anti-
TLR3 Ab, anti-TLR7 Ab, anti-TLR9 Ab, anti-NOD1 Ab,
anti-NOD2 Ab or control IgG for 30 min, followed by
FITC-conjugated secondary Ab at 4°C for another 30 min.
To calculate the percentage of positive cells, the baseline
cursor was set at a channel that yielded < 2% of events
positive with the isotype Ab control. Fluorescence to the
right was counted as specific binding.
Statistics
All experiments in this study were performed at least three
times to confirm the reproducibility of the results. For
most of the experiments, values are represented as the
mean ± S.D. of triplicate assays. The significance of differ-
ences between two means was evaluated by one-way
ANOVA using the Bonferroni or Dunnett method, and
values of P < 0.05 were considered to be significant.
Results
Treatment with anti-PR3 Abs up-regulated the expression 
of TLR2, TLR3, TLR4, TLR7, TLR9, NOD1 and NOD2 in 
human PBMCs
As mentioned above, we [32] recently reported that anti-
PR3 Abs up-regulated the expression of various TLRs and
NOD1/2 on human monocytic THP-1 cells, and endowed
the cells with the ability to produce inflammatory
cytokines at remarkable levels upon stimulation with var-
ious TLRs and NOD1/2 ligands. As it would be interesting
to investigate whether similar effects induced by mono-
clonal anti-PR3 Abs are also observed with PBMCs, we
examined the effects of anti-PR3 Abs on the expression of
various TLRs and NOD1/2 in PBMCs. PBMCs constitu-
tively expressed TLR2, 3, 4, 7, and 9, NOD1, and NOD2.
The incubation of PBMCs with 1 μg/ml of the anti-PR3
Abs resulted in the up-regulated expression of these mol-
ecules (Fig. 1), consistent with the results obtained with
the human monocytic cell line, THP-1. On the other
hand, equal concentrations of an isotype-matched IgG
were completely ineffective in this respect.
ANCA serum amplified IL-8 production triggered by TLR 
and NOD ligands in human monocytic cells
To further demonstrate the possible immunopathological
properties of ANCA from WG patients, we examined
whether the ANCA sera are capable of priming THP-1 cells
similarly to murine anti-PR3 Ab. We obtained sera from
patients with WG at Tohoku University Hospital, and car-
ried out experiments using the sera and human Abs puri-
fied from the sera. The titers of PR3-ANCA and MPO-
ANCA in serum were determined. All 7 sera (Q9-40, R9-7,
R9-10, S9-29, S9-31, S9-32, and 10–41) from 4 patients
were PR3-ANCA positive (> 3.0 titer) whereas none was
MPO-ANCA positive (< 1.3 titer) (Table 1). Therefore, the
seven PR3-ANCA-positive sera from WG patients were
compared with normal serum. We examined the produc-
tion of IL-8 upon stimulation with the respective ligands
(TLR2-agonistic FSL-1, TLR3-agonistic poly I:C, TLR4-ago-
nistic lipid A, TLR7-agonistic ssPoly U, NOD1-agonistic
FK156, and NOD2-agonistic MDP) after priming with the
sera. IL-8 production was significantly enhanced when
THP-1 cells were incubated with WG patients sera (closed
bar) as compared with normal serum (open bar) (Fig. 2).
The priming effects of WG patients' sera correlated well
with the PR3-ANCA titer; e.g. stronger priming effects
were observed with Q9-40 (PR3-ANCA titer 29.2) and R9-
10 (PR3-ANCA titer 19.1) and weaker priming effects
were observed with R9-7 (PR3-ANCA titer 3.8) and S9-29
(PR3-ANCA titer 3.5). These results clearly indicated that
PR3-ANCA in the sera from WG patients exerted a clear
priming effect similar to murine monoclonal anti-human
PR3 Abs in vitro.
PR3-ANCA sera and purified IgG amplified the production 
of IL-6, IL-8, MCP-1, and TNF-α triggered by TLR and 
NOD ligands in PBMCs
Next, we examined whether similar priming effects of
PR3-ANCA sera are also observed with PBMCs. Consistent
with the results in THP-1 cells (Fig. 2), PR3-ANCA sera
(R9-40 and R9-10) promoted various TLRs and NOD1/2
ligand-induced secretion of IL-8. It must be noted here
that the production of IL-6, MCP-1, and TNF-α in addi-
tion to IL-8 was also significantly up-regulated (Fig. 3).
PBMCs were incubated with PR3-ANCA sera for various
periods prior to being challenged with various TLRs and
NOD1/2 ligands. Although the magnitude of the priming
reaction differed among the respective ligands, similar
kinetic patterns were observed and only a slight elevation
was observed after a 2 h priming period and the ratio of
the response increased until 6 h, when maximal enhance-
ment was observed (data not shown). Thereafter, the
priming effect decreased, although longer priming peri-
ods were still effective in this respect (data not shown).
Although ANCA is autoantibodies characteristic of vascu-
litis diseases, PR3-ANCA and MPO-ANCA are known to
be negative in some kinds of vasculitis such as polyarteri-
tis nodosa and aortitis syndrome (Table 1). It must be
noted here that four ANCA-negative vasculitis sera (M10-
24, M10-29, H10-61, and G10-37) did not have any prim-
ing effects on PBMCs, contrary to two PR3-ANCA-positive
sera (Q9-40 and R9-10) (Fig. 3). To further confirm the
activity of PR3-ANCA other than the possible bioactive
factor(s) in the sera, we purified IgG from PR3-ANCA sera
by protein G. As shown in Fig. 4, purified IgG significantlyDiagnostic Pathology 2009, 4:23 http://www.diagnosticpathology.org/content/4/1/23
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up-regulated the production of IL-8 and MCP-1 in
PBMCs.
Discussion
Among ANCA, those targeting PR3 (PR3-ANCA) have a
strong and specific association with WG [4]. Besides their
significance as seromarkers, a pathogenic role has been
proposed for these autoantibodies in relation to their
capacity to activate leukocytes in vitro [9,10,12]. In the
present study, an alternative approach was chosen to
define the priming effect of ANCA against PR3 (PR3-
ANCA) from WG patients on inflammatory leukocyte
functions: human PBMCs were preincubated with sub-
stimulatory concentrations of PR3-ANCA and possible
augmented cell activation by various microbial PAMPs
was examined. As mentioned above, Hattar et al. [20] first
reported that anti-PR3 Abs primed human leukocytes for
the enhanced production of inflammatory cytokines
upon stimulation with TLR4-agonistic LPS or TLR2-ago-
nistic lipoteichoic acid in a CD14-dependent manner. In
our previous study [32], we demonstrated that incubation
with murine anti-PR3 Abs significantly up-regulated the
expression of various TLRs (TLR2, 3, 4, 7, and 9, NOD1,
and NOD2) in addition to CD14 in human monocytic
THP-1 cells. In this context, however, Hattar et al. [20]
found no increase in the expression of TLR2 and TLR4 by
FACS analysis after treatment with anti-PR3 Abs, and their
priming effects were CD14-dependent, but TLR2- and
TLR4-independent. It is unclear why they did not find an
increase in the expression of TLR. The difference in stain-
ing methods may be one reason; in their study, the cells
were directly stained with PE-labeled Abs targeting TLR2
or TLR4, whereas in our study the cells were stained with
various TLR or NOD Abs, followed by a FITC-conjugated
secondary Ab.
In our previous study [32], we examined the priming
effects of murine monoclonal anti-human PR3 Abs on
human monocytic THP-1 cells. We were interested in
whether similar effects would be observed with human
PBMCs and with serum and purified Ig isolated from WG
patients and control sera. In this study, we demonstrated
that PR3-ANCA serum from WG patients up-regulated the
expression of various TLRs and NODs in human PBMCs
Up-regulation of the expression of TLR2, TLR3, TLR4, TLR7, TLR9, NOD1, and NOD2 in human PBMCs in response to anti- PR3 Abs Figure 1
Up-regulation of the expression of TLR2, TLR3, TLR4, TLR7, TLR9, NOD1, and NOD2 in human PBMCs in 
response to anti-PR3 Abs. PBMCs were stimulated with murine anti-human PR3 Abs (1 μg/ml, filled graphs) or an isotype-
matched control IgG (1 μg/ml, bold line). After 6 h of incubation, the expression of cell-surface TLR2 and TLR4 and intracellu-
lar TLR3, TLR7, TLR9, NOD1, and NOD2, was assessed by flow cytometry. The thin lined curve is the staining with a control 
Ab. The results presented are representative of four different experiments.
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Enhancement of TLR and NOD ligand-induced IL-8 production in human monocytic THP-1 cells preincubated with PR3-ANCA  sera Figure 2
Enhancement of TLR and NOD ligand-induced IL-8 production in human monocytic THP-1 cells preincubated 
with PR3-ANCA sera. THP-1 cells (2 × 105 per ml) were preincubated for 6 h with 1:100 dilutions of PR3-ANCA sera from 
WG patients (Q9-40, R9-10, S9-31, R9-7, S9-29, S9-32, and D10-41) (closed bar) or with equal amounts of normal serum 
(sham incubation, open bar). Subsequently, THP-1 cells were challenged with FSL-1 (1 nM), poly I:C (1 μg/ml), lipid A (10 ng/
ml), ssPoly U (10 μg/ml), CpG DNA (1 μM), FK156 (100 μg/ml), or MDP (100 μg/ml) for 18 h. IL-8 levels in the culture super-
natants were determined by ELISA, and expressed as means ± S.D. *,# Significantly different from sham-incubated THP-1 cells 
and from respective cultures stimulated with the respective ligands alone. The results are representative of three different 
experiments.
n
o
n
e
F
S
L
-
1
P
o
l
y
 
I
:
C
l
i
p
i
d
 
A
s
s
P
o
l
y
U
C
p
G
 
D
N
A
F
K
1
5
6
M
D
P
n
o
n
e
F
S
L
-
1
P
o
l
y
 
I
:
C
l
i
p
i
d
 
A
s
s
P
o
l
y
U
C
p
G
 
D
N
A
F
K
1
5
6
M
D
P
Normal serum
R9-10
0
50
100
150
200
I
L
-
8
 
(
n
g
/
m
l
)
Norma serum
Q9-40
*
#
*
#
*
#
*
#
*
#
*
#
*
#
Normal serum
S9-29
Normal serum
S9-31
Normal serum
D10-41
Normal serum
S9-32
0
50
100
150
200
I
L
-
8
 
(
n
g
/
m
l
)
Normal serum
R9-7
0
50
100
150
200
I
L
-
8
 
(
n
g
/
m
l
)
0
50
100
150
200
I
L
-
8
 
(
n
g
/
m
l
)
0
50
100
150
200
I
L
-
8
 
(
n
g
/
m
l
)
0
50
100
150
200
I
L
-
8
 
(
n
g
/
m
l
)
0
50
100
150
200
I
L
-
8
 
(
n
g
/
m
l
)
* *
*
*
*
* *
*
#
*
#
*
#
*
# *
#
*
#
*
#
*
#
*
#
*
#
*
# *
#
*
#
*
#
*
#
*
#
*
#
*
#
*
#
*
#
*
#
*
#
*
#
*
#
*
# *
#
*
#
*
#
*
#
*
#
*
#
*
#
*
#
#
* *
#
#
#
#
#Diagnostic Pathology 2009, 4:23 http://www.diagnosticpathology.org/content/4/1/23
Page 7 of 10
(page number not for citation purposes)
Enhancement of TLR and NOD ligand-induced production of IL-8, MCP-1, IL-6, and TNF-α in human PBMCs preincubated  with PR3-ANCA sera Figure 3
Enhancement of TLR and NOD ligand-induced production of IL-8, MCP-1, IL-6, and TNF-α in human PBMCs 
preincubated with PR3-ANCA sera. PBMCs (donor 1 and 2, 2 × 105 cells per ml) were preincubated for 6 h with a 1:20 
dilution of PR3-ANCA sera (Q9-40 or R9-10 from WG patients or ANCA-negative vasculitis seum (M10-24, M10-29, H10-51, 
or G10-37) (closed bar), or with equal amounts of normal serum (sham incubation, open bar). Subsequently, PBMCs were 
challenged with FSL-1 (1 nM), poly I:C (1 μg/ml), lipid A (10 ng/ml), ssPoly U (10 μg/ml), FK156 (100 μg/ml), or MDP (100 μg/
ml) for 18 h. The levels of IL-6, IL-8, MCP-1, and TNF-α in the culture supernatants were determined by ELISA, and expressed 
as means ± S.D. *,# Significantly different from sham-incubated PBMCs and from respective cultures stimulated with the respec-
tive ligands alone. The results are representative of four different experiments.
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(Fig. 1) and primed PBMCs to produce proinflammatory
cytokines such as IL-6, IL-8, MCP-1, and TNF-α via TLRs
and NODs (Figs. 2 and 3). We solely used chemically syn-
thesized PAMPs, because natural microbial cell surface
preparations are inevitably contaminated with minor bio-
active components that might have confused the results.
Therefore, these results clearly indicated that PR3-ANCA
primed TLR2-, 3-, 4-, 7-, and 9-, NOD1-, and 2-dependent
cell activation in PBMCs. Although ANCA is autoantibod-
ies characteristic of vasculitis diseases, PR3-ANCA and
MPO-ANCA are known to be negative in some kinds of
vasculitis such as polyarteritis nodosa and aortitis syn-
drome (Table 1). It must be noted here that four ANCA-
negative vasculitis sera did not have any priming effects
on PBMCs in PBMCs, contrary to two ANCA-positive sera
(Fig. 3). Purified IgG from WG serum also significantly
primed PBMCs to produce proinflammatory cytokines
(Fig. 4). These findings certainly strengthen our conclu-
sion and the relevance of our work to the human situa-
tion.
It is conceivable that microbial components exhibit pow-
erful immuno-adjuvant activities through the activation
of antigen-presenting cells via TLR and NOD pathways
against various antigens, including autoantigens, which in
turn might induce severe autoimmune diseases. In fact, in
animal models, NOD2-agonistic MDP induces autoim-
mune diseases such as experimental encephalomyelitis,
orchitis, uveoretinitis, thyroiditis, and polyarthritis [34].
In contrast, our study showed a completely different
model for the possible induction of autoimmune diseases
by microbial components. Namely, microbial TLR- and
NOD-ligands possibly induced tissue destruction through
excessive inflammatory responses by triggering the activa-
tion of PR3-ANCA-primed cells. The background for the
present experimental rationale is based on the fact that the
disease activity in WG, which is paralleled by a rising PR3-
ANCA titer [4,8], appears to be triggered by microbial
infections [9,35-37]. As suggested by Condliffe et al. [38]
and Hallett and Lloyds [39], in vivo, the response of leu-
kocytes to microbial depends on the state of cellular acti-
Enhancement of TLR and NOD ligand-induced production of IL-8 and MCP-1 in human PBMCs preincubated with purified IgGs  from PR3-ANCA sera Figure 4
Enhancement of TLR and NOD ligand-induced production of IL-8 and MCP-1 in human PBMCs preincubated 
with purified IgGs from PR3-ANCA sera. PBMCs (donor 1 and 2, 2 × 105 cells per ml) were preincubated for 6 h with 
PR3-ANCA IgG (50 μg/ml, Q9-40 or R9-10) (closed bar) or with an equal amount of normal IgG (sham incubation, open bar). 
Subsequently, PBMCs were challenged with FSL-1 (1 nM), poly I:C (1 μg/ml), lipid A (10 ng/ml), ssPoly U (10 μg/ml), FK156 
(100 μg/ml) or MDP (100 μg/ml) for 18 h. The levels of IL-8 and MCP-1 in the culture supernatants were determined by ELISA, 
and expressed as means ± S.D. *,# Significantly different from sham-incubated PBMCs and from respective cultures stimulated 
with the respective ligands alone. The results are representative of four different experiments.
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vation, varying from "dormant" via "primed" to "fully
activated". Priming is a key mechanism involved in the
regulation of the leukocyte-dependent host defense.
Although they do not directly activate neutrophil and
monocyte functions, priming agents induce a "sensitiza-
tion" of the leukocytes for subsequent stimulation with
naturally occurring agonists, such as microbe-derived
products. In addition to the important roles of ANCA in
the regulation of inflammatory leukocyte functions, the
phenomenon of leukocyte priming by PR3-ANCA may
also be relevant to the pathogenesis of inflammation.
Indeed, in active WG, neutrophils and monocytes display
a phenotype attributable to a state of cellular preactiva-
tion with the enhanced surface expression of activation
markers such as CD11b and CD64 [11,40].
PR3-ANCA, being only weak direct activators of mono-
cytes and neutrophils to release cytokines per se, exert a
definite priming effect on these leukocytes, enhancing
their responsiveness to secondary stimulation with micro-
bial PAMPs. The up-regulation of various pattern recogni-
tion receptors, including TLRs and NODs, acting as
respective PAMPs, was characterized as one mechanism
underlying the ANCA-elicited priming response. Such
cooperation between PR3-ANCA and microbial PAMPs
may well trigger exacerbations of disease activity during
infections and contribute to the persistence of inflamma-
tory lesions, which might be a novel model for the patho-
genesis of autoimmune diseases.
Conclusion
In conclusion PR3-ANCA prime human mononuclear
cells to produce cytokines upon stimulation with various
microbial components by up-regulating the TLR and
NOD signaling pathway, and these mechanisms may par-
tially participate in inflammatory process in WG.
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